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Abstract (283/300 words) 57 
Background and aims: The activity of CYP2A6, the major nicotine-inactivating enzyme, is 58 
measurable in smokers using the nicotine metabolite ratio (NMR; 3’hydroxycotinine/cotinine). 59 
Due to its role in nicotine clearance, the NMR is associated with smoking behaviours and 60 
response to pharmacotherapies. The NMR is highly heritable (~80%), and on average lower in 61 
African Americans (AA) versus Whites. We previously identified several reduce and loss-of-62 
function CYP2A6 variants common in individuals of African descent. Our current aim was to 63 
identify novel genetic influences on the NMR in AA smokers using genome-wide approaches. 64 
Design: Genome-wide association study (GWAS). Setting: Multiple sites within Canada and the 65 
United States. Participants: AA smokers from two clinical trials: Pharmacogenetics of Nicotine 66 
Addiction Treatment (PNAT)-2 (NCT01314001; n=504) and Kick-it-at-Swope (KIS)-3 67 
(NCT00666978; n=450). Measurements: Genome-wide SNP genotyping, the NMR 68 
(phenotype), and population substructure and NMR covariates. Findings: Meta-analysis 69 
revealed three independent chromosome 19 signals (rs12459249, rs111645190, and 70 
rs185430475) associated with the NMR. The top overall hit, rs12459249 (P=1.47e-39; beta=0.59 71 
per C (versus T) allele, SE=0.045), located ~9.5kb 3’ of CYP2A6, remained genome-wide 72 
significant after controlling for the common (~10% in AA) non-functional CYP2A6*17 allele. In 73 
contrast, rs111645190 and rs185430475 were not genome-wide significant when controlling for 74 
CYP2A6*17. In total, 96 signals associated with the NMR were identified; many were not found 75 
in prior NMR GWASs in European descent individuals. The top hits were also associated with 76 
the NMR in a third cohort of AA (KIS2; n=480). None of the hits were in UGT or OCT2 genes. 77 
Conclusions: Three independent chromosome 19 signals account for ~20% of the variability in 78 
the nicotine metabolite ratio in African-American smokers. The hits identified may contribute to 79 
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The prevalence of cigarette smoking remains high despite widespread tobacco control 90 
efforts; recent estimates suggest 15% of Americans are current smokers (1). A growing segment 91 
of American smokers are light smokers (smoke ≤10 cigarettes/day) who, like heavy smokers, 92 
experience elevated risks of disease and mortality compared to never smokers (2). Smoking 93 
behaviour and smoking-related morbidity differ by ethnicity. For instance, although African 94 
American (AA) smokers on average smoke fewer cigarettes/day than European American (EA) 95 
smokers, the level of total nicotine equivalents, a biomarker of total nicotine intake, is similar in 96 
AA and EA smokers, suggesting more intensive smoking (e.g., greater puff volume) among AAs 97 
(3). At an equivalent number of cigarettes per day, the risk for lung cancer is higher in AA 98 
compared to EA smokers, perhaps due in part to more intensive smoking and, therefore, greater 99 
exposure to tobacco-specific nitrosamines and other harmful chemicals (4). Of note, AA (vs. EA) 100 
smokers are also more likely to make quit attempts and are less likely to achieve cessation (5).  101 
Understanding the factors that contribute to this increased risk for lung cancer and reduced 102 
likelihood of cessation among AA smokers will help guide treatment interventions for this 103 
population. 104 
Nicotine is the predominant psychoactive compound in cigarettes (6). Nicotine  105 
undergoes metabolic inactivation by the hepatic CYP2A6 enzyme to cotinine, which is further 106 
metabolized to 3’hydroxycotinine exclusively by CYP2A6 (7, 8). The CYP2A6 gene, located on 107 
chromosome 19q13.2, contains several functional polymorphisms, leading to inter-individual 108 
variation in the rate of nicotine clearance (9). The nicotine metabolite ratio (NMR; 109 
3’hydroxycotinine/cotinine) is an established and validated phenotypic marker of CYP2A6 110 
activity in smokers; it is associated with CYP2A6 genotype and correlates with nicotine clearance 111 
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(10-15). The NMR is 80% heritable (estimated in Finnish European twins) (16); in addition to 112 
genetic influences, the NMR captures relatively minor environmental (e.g., mentholated cigarette 113 
use and BMI) (17, 18) sources of variation in CYP2A6 activity. 114 
The NMR has been evaluated as a clinical marker for personalizing smoking cessation 115 
treatment. Compared to higher NMR, lower NMR (i.e., slower nicotine metabolism) is 116 
associated with higher cessation rates with behavioural counseling (19) and among nicotine 117 
patch treated smokers (20-22). In a placebo-controlled bupropion trial, bupropion increased quit 118 
rates over placebo in those with higher but not lower NMR (19). In smokers prospectively 119 
randomized to treatment based on the NMR (PNAT2 Trial; NCT01314001), those with higher, 120 
but  not lower, NMR had higher quit rates on varenicline (versus nicotine patch) (23). Number-121 
needed-to-treat analyses in smokers with higher NMR indicated 5 and 26 smokers would need to 122 
be treated with varenicline (versus placebo) and nicotine patch (versus placebo), respectively, for 123 
one smoker to quit, again indicating the superiority of varenicline for those with higher NMR 124 
(23); in those with lower NMR these values were 8 and 10, respectively. In addition, those with 125 
lower (versus higher) NMR experienced greater negative side effects on varenicline (versus 126 
placebo) (23). Thus, the evidence indicates that smokers with higher NMR show greater benefit 127 
from varenicline or bupropion compared to behavioural counseling or nicotine patch, while 128 
smokers with lower NMR are treated more effectively and safely with nicotine patch and/or 129 
behavioural counseling. 130 
Variability in CYP2A6 genetics and/or the NMR also influences the level of tobacco 131 
consumption (from cigarettes and smokeless tobacco), dependence, and risk for tobacco-related 132 
disease; smokers with slower metabolism (i.e., slow CYP2A6 metabolism groups or lower NMR 133 
values) generally show lower consumption, dependence, and disease risk (17, 24-26).  134 
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The NMR varies by ethnicity, with AA smokers having on average lower NMR (and 135 
nicotine clearance) versus smokers of EA descent (17, 27), due in part to the higher frequency of 136 
known CYP2A6 reduced or loss-of-function variants in AAs (28); many of these variants, 137 
including *23 , *24, *25, *28, *35, and *39-*45 (29-32), were identified and functionally 138 
characterized by our group using in vitro (e.g., CYP2A6 cDNA expression system), ex vivo (e.g., 139 
human liver bank), and in vivo (e.g., human smokers) nicotine metabolism rate assessments. 140 
These variants are common (>1% frequency) in AA, but exceedingly rare in EA populations. 141 
CYP2A6*17, with an allele frequency of 10% in AA (33), explains ~8% of the variability in the 142 
NMR (unpublished observations in the KIS3 trial (34)). Although >40 CYP2A6 variants have 143 
been identified and functionally characterized, estimates in Finnish Europeans indicate only 144 
~30% of NMR variation is currently explained by detected CYP2A6 variants (16). To date, three 145 
NMR GWASs have been performed, predominantly or exclusively in Whites who were non-146 
treatment-seeking smokers (only 413 AA total among >4000 total participants from three 147 
studies) (16, 35, 36); no GWAS has examined the NMR in smokers seeking treatment, for whom 148 
personalized medicine approaches based on CYP2A6/the NMR would be targeted. 149 
Here we performed a GWAS of the NMR, assessed at baseline when participants were 150 
smoking ad libitum (i.e., when NMR is stable (13)), in AA smokers from two smoking cessation 151 
clinical trials and genotyped top hits in a third trial to confirm associations with the NMR.  The 152 
first involved heavy smokers (10 cigarettes/day) screened for the PNAT2 trial (NCT01314001), 153 
where smokers were randomized to placebo, nicotine patch, or varenicline (23). The second 154 
involved light-smokers (≤10 cigarettes/day) that participated in a placebo-controlled bupropion 155 
trial for smoking cessation (KIS3 trial; NCT00666978) (34, 37). To further investigate 156 
associations between selected GWAS hits and the NMR, we utilized a third sample of AA light-157 
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smokers from a placebo-controlled nicotine gum trial (KIS2 trial) (38). Our goals were to better 158 
understand the genetic underpinnings of the NMR in AA smokers, and to compare genetic 159 
signals with those previously found in European populations to identify potential common and 160 
unique genetic influences on the NMR in AA smokers.  161 




The original trial protocols were approved by institutional review boards at all participating sites 164 
and at the University of Toronto. Individuals providing written informed consent for DNA 165 
sample collection and release of de-identified information to investigators underwent 166 
genotyping. 167 
 168 
PNAT2 Clinical Trial (NCT01314001) (23). Participant characteristics and trial procedures are 169 
described in detail elsewhere (17, 23). Briefly, eligible adult (aged 18-65 years) smokers (≥10 170 
cigarettes/day) from four clinical sites (University of Pennsylvania, University of Toronto/Centre 171 
for Addiction and Mental Health, MD Anderson, and the State University of New York at 172 
Buffalo) were randomized prospectively based on their pre-treatment NMR to receive placebo, 173 
nicotine patch, or varenicline treatment for smoking cessation.  174 
 175 
KIS3 Clinical Trial (NCT00666978) (34). Participant characteristics and clinical trial 176 
procedures are described in detail elsewhere (34, 37). Briefly, eligible adult (aged ≥18 years) 177 
light-smokers (≤10 cigarettes/day) from Kansas City, Missouri, were randomized to bupropion 178 
plus health education or placebo plus health education for smoking cessation.  179 
 180 
KIS2 Clinical Trial (38). Participant characteristics and clinical trial procedures are described in 181 
detail elsewhere (38). Briefly, eligible adult (aged ≥18 years) light-smokers (≤10 cigarettes/day) 182 
from Kansas City, Missouri, were randomized to nicotine gum or placebo and health education 183 




Genome-Wide SNP Genotyping. Genome-wide SNP genotyping (PNAT2 and KIS3) was 186 
conducted using the Illumina HumanOmniExpressExome-8 v1.2 array (Illumina, San Diego, 187 
CA, USA) at the Centre for Applied Genomics at the Hospital for Sick Children (Toronto, ON, 188 
Canada). A custom iSelect® add-on comprising 2,688 variants (Table S1) was included based 189 
on previous associations with nicotine metabolism and/or smoking behaviours including 190 
cessation; these variants cover the CYP2ABFGST cluster (chromosome 19), the CHRNA5-A3-B4 191 
nicotinic receptor cluster (chromosome 15), OCT2 (chromosome 6), and the UGT2B cluster 192 
(chromosome 4). 193 
 194 
TaqMan SNP Genotyping. Candidate chromosome 19 polymorphisms (rs12459249, 195 
rs111645190, rs2644890, and rs111825958) were genotyped in KIS2 using an ABI ViiATM 7 196 
Real-Time PCR System and TaqMan® SNP genotyping assays (Thermo Fisher Scientific, 197 
Waltham, Massachusetts, USA) according to the manufacturer’s protocol. The resulting 198 
genotype frequencies for all four SNPs were in Hardy-Weinberg Equilibrium (each P>0.05). 199 
 200 
Quality Control (QC) Procedures for Genome-Wide SNP Genotyping and Imputation. QC 201 
procedures for sample and variant were carried out, and genotypes were imputed, prior to 202 
analysis as outlined in Figures S1 and S2. After identifying and removing samples with 203 
discordant sex information and excessive missingness of genetic data, the PNAT2 and KIS3 204 
samples were combined to assess relatedness and ancestry to ensure a) an appropriate level of 205 
independence of individuals, and b) use of an equivalent threshold for determining ancestry. 206 
Individuals of AA ancestry, determined using principal components analysis in combination with 207 
data from HapMap 3 (Figure S2), were selected for further analyses. In PNAT2 and KIS3, 208 
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98.5% and 96.6% of African descent smokers, respectively, had genetic ancestries concordant 209 
with self-reported ancestry. Following QC, the final number of individuals and markers available 210 
was: n=506 PNAT2 AAs (251 males, 255 females), 733,629 variants; and n=458 KIS3 AAs (154 211 
males, 304 females), 742,493 variants (Figure S1). QC procedures were performed using PLINK 212 
(version 1.07) (39) and R software. 213 
The PNAT2 AA and KIS3 AA genotypes were then phased using SHAPEIT (40) and 214 
imputed using IMPUTE2 (41). The genomic data were divided into individual chromosomes 215 
(chromosomes 1-22) and aligned against the reference panel (Phase I release of 1000 Genomes). 216 
Following the elimination of duplicated SNPs, a second alignment step was performed, followed 217 
by pre-phasing and imputation, according to previously established protocols (41-44). Variants 218 
with INFO (i.e., quality) scores > 0.4 (threshold of 0.3 or higher is recommended (45)) and a 219 
minor allele frequency > 1% were selected for further analyses. Overall, 17,970,591 and 220 
17,919,969 variants in PNAT2 and KIS3, respectively, were available for analysis. 221 
 222 
Assessment of Imputation Quality for CYP2A6 Relative to Other Chromosome 19 Genes. 223 
CYP2A6 shares high homology with CYP2A7 and CYP2A13, which can confound the accuracy 224 
of CYP2A6 calls (46). IMPUTE2 info (i.e., imputation quality) scores for CYP2A6 were 225 
compared to those of EIF3K and TGFβ1, located outside of this region of high homology 226 
(~2,222kb 5’ and ~480kb 3’ of CYP2A6, respectively). 227 
 228 
Phenotype: Nicotine Metabolite Ratio. The levels of cotinine and 3’hydroxycotinine were 229 
determined from blood samples collected at intake when participants were smoking ad libitum 230 
using identical liquid chromatography-tandem mass spectrometry according to previously 231 
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established protocols (10, 11, 47). The NMR (3’hydroxycotinine/cotinine) was square-root-232 
transformed to correct for positive skew (Figure S3). Individuals with cotinine values below 10 233 
ng/ml, suggestive of non-daily smoking (48), were excluded from analyses.  234 
 235 
Covariates. Analyses in PNAT2 and KIS3 included principal components 1 and 2 as covariates 236 
to control for possible effects of population stratification (49). To identify additional covariates, 237 
we performed separate linear regression analyses to identify whether factors previously 238 
significantly associated with the NMR in the whole PNAT2 sample (sex, age, estrogen-239 
containing therapy use, BMI, alcohol use (17)) were associated with square-root NMR (with 240 
P<0.10) in PNAT2 AA and KIS3 AA. In PNAT2, the following were included as covariates: sex 241 
(P=0.038), age (P=0.006), BMI (P=0.038), and use of menthol cigarettes (P=0.063).  In KIS3, 242 
the following were included as covariates: sex (P=0.056), age (P<0.001), and BMI (P<0.001), 243 
but not mentholated cigarette use (P=0.60).  244 
 245 
Statistical Analyses 246 
GWAS of the NMR. SNPTEST (version 2.5.2) was used to identify genetic associations with 247 
the NMR separately in PNAT2 and KIS3; chromosomes 1-22 were analyzed separately. 248 
Frequentist additive models were specified, and genotype uncertainty was controlled for by using 249 
the “-method expected” option (uses expected genotype counts or genotype dosages). We also 250 
performed a separate set of analyses specifying frequentist dominant models, and the “-method 251 
score” option, and acquired similar results. Variants with P<5e-8 were considered to be 252 
significant at the genome-wide level (50). 253 
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A meta-analysis of chromosome 19 results, adjusting for population sub-structure and 254 
NMR covariates, was then performed using META (version 1.7) (51). The genomic control 255 
inflation factor (λ) (calculated using PLINK) for the full GWAS analysis (chromosomes 1-22) 256 
was 1 and the QQ plots showed no deviation from the null (Figure S4). Because the same 257 
phenotype (square-root NMR; Figure S3) measured on the same scale was specified in both 258 
cohorts, the inverse-variance method based on a fixed-effects model was implemented (16). 259 
Variants with INFO scores ≥0.50 were included in the meta-analysis; a total of 367,834 markers 260 
were in the union list. 261 
 262 
Conditional Analysis of Chromosome 19 NMR Results in PNAT2 and KIS3. To identify 263 
putatively independent chromosome 19 signals associated with the NMR, conditional analyses 264 
were performed (16); the variant with the smallest P-value in the meta-analysis (i.e., rs12459249) 265 
was considered the first independent signal, and then ‘conditioned on’ (i.e., entered as a 266 
covariate) in subsequent frequentist additive models performed separately in PNAT2 and KIS3. 267 
These results were meta-analyzed, with the variant with the smallest P-value (i.e., the second 268 
independent signal) entered as a covariate along with the first independent signal in the second 269 
round of conditional analyses. The procedure was repeated until no additional significant (i.e., 270 
P<5e-8) signals emerged. 271 
 272 
Proportion of Variation in the NMR Accounted for by rs12459249, rs111645190, 273 
rs2644890, and rs11879604. Separate linear regression models were used to determine the 274 
proportion of NMR variability attributable to selected variants (three-genotype coding), using 275 
SPSS version 23 (IBM, Armonk, New York, USA). The outcome measure was square-root 276 
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NMR. Models in PNAT2 controlled for sex, age, BMI, and the use of mentholated cigarettes, 277 
while models in KIS3 and KIS2 controlled for sex, age, and BMI. The proportion of NMR 278 
variability accounted for by each variant was calculated by squaring the variant’s part correlation 279 
coefficient and multiplying by 100.  280 
 281 
Final Sample Sizes 282 
Two of the n=506 PNAT2 AA participants were excluded from further analyses due to missing 283 
and outlying (>4 SD from the mean) square-root NMR values (Figure S1). After additionally 284 
excluding individuals with missing menthol covariate data (n=98), n=406 PNAT2 participants 285 
were available for GWAS analysis. Eight KIS3 AA participants were excluded due to having 286 
cotinine levels <10 ng/ml (Figure S1) which suggests non-daily smoking, and one participant 287 
was missing BMI data. Thus, n=449 KIS3 participants were available for GWAS analysis. Of the 288 
n=495 KIS2 individuals with pre-treatment NMR that provided a blood sample and consented to 289 
genetic testing, n=15 were excluded from further analyses due to insufficient quantity of blood 290 
remaining (n=7), cotinine level <10 ng/ml (n=6), and outlying (>4 SD from the mean) square-291 
root NMR values (n=2). Thus, the final KIS2 AA sample comprised n=480 individuals. 292 
 293 




Characteristics of the final analyzed sample are provided in Table 1. These values are 296 
similar to those reported in the full trial samples (17, 34, 38). In PNAT2 and KIS3, the median 297 
info score (out of 1, with higher scores indicating higher imputation quality) for CYP2A6 was 298 
0.9, compared to 0.6 and 0.9 for EIF3K and TGFβ1, respectively, suggesting adequate 299 
imputation quality for CYP2A6. In each of PNAT2 and KIS3, 98% of the variants significantly 300 
associated with the NMR at the genome-wide level (P<5e-8) were located on chromosome 19, 301 
within or near to (several kilobases) the CYP2A6 gene. Of note, no genetic variants in UGT 302 
enzymes (involved in the glucuronidation of nicotine, cotinine, and 3’hydroxycotinine (52)) or 303 
the OCT2 transporter (involved in nicotine transport (52)) reached genome-wide significance in 304 
either PNAT2 or KIS3. 305 
 306 
Meta-analysis of Chromosome 19 NMR Results in PNAT2 and KIS3 AA Smokers 307 
Ninety-six genome-wide significant chromosome 19 variants were identified after 308 
adjusting for cohort-specific principal components 1 and 2 and NMR covariates (top 10 variants 309 
in Table 2, full list in Table S2; all top variants had info (quality) scores >0.9). Of note, the top 310 
10 variants did not differ (similar betas and P-values) when four principal components were 311 
adjusted for. The top (smallest P-value) overall variant in the meta-analysis was rs12459249 312 
(I2=0; Heterogeneity P=0.80), with a combined P-value of 1.47e-39 (Table 2); this was the top 313 
variant in PNAT2 (Figure 1A), and the second-most significant variant in KIS3 (Figure 1B). 314 
Overall, 58 (60.4%) of the 96 significant hits were not genome-wide significant in the GWAS of 315 
the NMR performed in ~1,500 Finnish European smokers (16); the most significant of these 58 316 
AA hits in the meta-analysis was rs111825958 (I2=0.66; Heterogeneity P=0.32), with a 317 
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combined P-value of 5.93e-26 (Table 2). Effect sizes and P-values for the top variants in each 318 
population (PNAT2 and KIS3) are also provided in Table 2. In a separate meta-analysis that 319 
additionally controlled for cigarettes/day and menthol use in KIS3, the top hit was rs11878604 320 
with a beta of -0.68 (SE=0.069; P=5.65e-23 per C vs. T allele), while rs12459249 was the second 321 
top hit with a beta of 0.59 (SE=0.063; P=5.73e-21 per C vs. T allele); these effect sizes did not 322 
substantially differ from those in the primary analysis (Table 2).  323 
 324 
Conditional Analysis of Chromosome 19 NMR Results in African American Smokers 325 
 Conditional analyses of the chromosome 19 NMR results in PNAT2 and KIS3 AA 326 
smokers revealed a total of three independent signals associated with the NMR; the first two 327 
were tagged by rs12459249 and rs111645190 (Table 3). In PNAT2 and KIS3, rs12459249, 328 
located ~9.5kb 3’ of CYP2A6, substantially altered NMR (Figure 2A and 2B), explaining 17.1% 329 
and 15.3% of the variability in the NMR, respectively. The association between the rs12459249 330 
variant and the NMR also replicated in KIS2 (P=1.30e-17; Figure 2C). After conditioning on 331 
rs12459249, rs111645190 (located ~5.5kb 5’ of CYP2A6) had a P-value of 1.19e-11 (beta=-0.42 332 
per A versus G allele; SE=0.062; Table 3 and Figure 1C and 1D). In PNAT2 and KIS3, the 333 
influence of rs111645190 on the NMR was also pronounced (Figure 2D and 2E), explaining an 334 
additional 2.9% and 5.2% of the variation in the NMR, respectively, after controlling for 335 
rs12459249. Of note, in a separate meta-analysis that additionally controlled for cigarettes/day 336 
and menthol use in KIS3, the effect size for rs111645190 was similar to the primary analysis 337 
(Table 2) (beta=-0.67, SE=0.085; P=4.10e-15 per A vs. G allele). The association for 338 
rs111645190 also replicated in KIS2 (P=1.77e-7; Figure 2F). After conditioning on both 339 
rs12459249 and rs111645190, a third independent signal emerged, tagged by rs185430475 340 
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(MAF = 2%; located >10MB 3’ of CYP2A6), with a P-value of 1.94e-8 (beta=1.27 per G versus 341 
C allele; SE=0.23). Of note, the rs185430475 variant was not significantly associated with the 342 
NMR in the meta-analysis (beta = 1.25 per G versus C allele; SE=0.26; P=9.26e-7), nor in 343 
PNAT2 (beta = 1.02 per G versus C allele; SE=0.33; P=0.0023) or KIS3 (beta = 1.47 per G 344 
versus C allele; SE=0.34; P=2.39e-5). 345 
 346 
Genetic Variants Associated with the NMR in African American Smokers (PNAT2 and 347 
KIS3 Analyzed Separately) 348 
In PNAT2, 56 chromosome 19 variants significantly (P<5e-8) associated with the NMR 349 
were identified after adjusting for population sub-structure; 53 remained significant after 350 
additionally controlling for NMR covariates (Table S3). Controlling for clinical site did not 351 
substantially alter the findings (53 hits were still observed; rs12459249 remained the top hit with 352 
a beta (SE) per C vs. T allele of 0.61 (0.066); P=1.39e-18). A variant within chromosome 2 was 353 
also significantly associated with the NMR (rs16984355; P=2.1e-9). The top overall variant 354 
identified in PNAT2 was rs12459249 (Figure 1A and 2A), explaining 17.1% of NMR variation. 355 
Thirty-five of the 56 significant hits were not genome-wide significant in the ~1500 Finnish 356 
Europeans (16); the most significant of these hits was rs2644890 (Table 2 and Figure 3A and 357 
4A), explaining 2.3% of NMR variation after controlling for rs12459249. Per 1000 Genomes, 358 
rs12459249 and rs2644890 are not in appreciable linkage disequilibrium (LD) in individuals of 359 
African descent (r2<0.20). The rs2644890 variant was also significantly associated with the 360 
NMR in KIS3 (P=1.24e-7; Figure 3B and 4B) and KIS2 (P=5.60e-5; Figure 4C).  361 
In KIS3, 46 chromosome 19 variants significantly (P<5e-8) associated with the NMR 362 
were identified after adjusting for population sub-structure; 38 (>80%) of these variants were 363 
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also genome-wide significant in PNAT2. After additionally controlling for NMR covariates, 44 364 
chromosome 19 variants remained significant (Table S4). A variant within chromosome 2 was 365 
also significantly associated with the NMR (rs139278877; P=5.2e-9). The top overall variant in 366 
KIS3 was rs11878604 (Table 2), accounting for 17.1% of NMR variation; rs11878604 was also 367 
significant in PNAT2 (P=9.60e-17; Table 2). Twenty-eight of the 46 significant hits in KIS3 368 
were not genome-wide significant in the ~1500 Finnish Europeans (16); the most significant of 369 
these hits was rs111825958 (Table 2 and Figure 3D and 4E), which explained 0.8% of NMR 370 
variation after controlling for rs11878604. Per 1000 Genomes, rs11878604 and rs111825958 are 371 
in moderate LD in individuals of African descent (r2=0.39). The rs111825958 variant was also 372 
significantly associated with the NMR in PNAT2 (P=4.11e-10; Figure 3C and 4D) and KIS2 373 
(P=4.25e-11; Figure 4F).  374 
Of note, the previously characterized nonsynonymous rs28399454 (C>T) variant in exon 375 
7 of CYP2A6, which defines the non-functional CYP2A6*17 allele present at high frequency in 376 
AAs (33), was significantly associated with the NMR in both PNAT2 (P=4.56e-11; beta=-0.68 377 
per T versus C allele; SE=0.10, allele frequency=10.5%) and KIS3 (P=5.90e-11; beta=-0.68 per 378 
T versus C allele; SE=0.10 allele frequency=11.0%). In a model that controlled for population 379 
sub-structure, cohort-specific NMR covariates, and additionally for rs28399454, the P-values for 380 
rs12459249 in PNAT2 and KIS3 increased somewhat (from 1.59e-18 to 1.03e-11, and from 381 
3.41e-19 to 1.13e-11, respectively). However, the P-value for rs111645190 was not genome-382 
wide significant in each of PNAT2 and KIS3 after controlling for rs28399454: P-values 383 
increased from 4.10e-10 to 0.023 in PNAT2, and from 6.88e-14 to 0.011 in KIS3. 384 




This is the first NMR GWAS conducted exclusively in African Americans. We identified 387 
three independent signals tagged by rs12459249, rs111645190, and rs185430475. These three 388 
signals were not in LD (r2<0.20) with (in the 1000 Genomes Project AFR population) the four 389 
independent signals (rs56113850, rs113288603, esv2663194, and rs12461964) identified in the 390 
first NMR GWAS, which we conducted in ~1500 Finnish European smokers (16). Together 391 
these findings extend our prior work (e.g., for *23 , *24, *25, *28, *35, and *39-*45 (29-32)) 392 
showing the existence of unique genetic influences on CYP2A6 function and the NMR in AA. 393 
The top independent signal, rs12459249, located ~9.5kb 3’ of CYP2A6, was also genome-wide 394 
significant in the Finnish sample (16), suggesting a common ancestral origin; however, it is 395 
possible that rs12459249 tags different functional variants in different populations. After 396 
controlling for rs28399454, the defining variant in the CYP2A6*17 allele present at high 397 
frequencies in AA (33), the P-values for rs12459249 in PNAT2 and KIS3 increased only 398 
somewhat (from ~10-18 to 10-11), suggesting at least a portion of the influence of rs12459249 on 399 
the NMR is independent of CYP2A6*17. A recent study examined the NMR following oral or 400 
i.v. administration of labeled nicotine and cotinine in n=212, n=51, and n=49 individuals of EA, 401 
Asian American, and AA ancestry, respectively, and identified rs12459249 as the top-ranked 402 
SNP overall; rs12459249 was also non-significantly associated with the NMR (P=5.76e-6) in the 403 
small sample of AA (35).  404 
The second independent signal was tagged by rs111645190, located ~5.5kb 5’ of 405 
CYP2A6. The top two independent variants (rs12459249 and rs111645190) explained ~20% of 406 
NMR variation, comparable to the amount of variability captured in the ~1500 Finnish European 407 
smokers (16), where the independent signals explained ~18-31% of NMR variation. However, 408 
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the influence of rs111645190 on the NMR was no longer significant in either PNAT2 or KIS3 409 
after controlling for rs28399454 (CYP2A6*17 allele), suggesting this second independent signal 410 
is largely driven by rs28399454 (33). 411 
Of note, over half (~60%) of the 96 hits found in the meta-analysis were not genome-412 
wide significant in the ~1500 Finnish Europeans (16), in part reflecting unique population LD 413 
structure. The top unique variant in the meta-analysis, rs111825958, was also associated with the 414 
NMR in KIS2 (38). After controlling for rs28399454 (CYP2A6*17), the P-values in PNAT2 and 415 
KIS3 increased from 4.11e-10 to 0.018, and from 5.28e-16 to 1.18e-5, respectively, suggesting, 416 
as for rs111645190, that rs28399454 explains a large portion of the influence of rs111825958 on 417 
the NMR. 418 
Our previous NMR GWAS in ~1500 Finnish European smokers (16) identified >700 hits, 419 
all found on chromosome 19q13 in or near to the CYP2A6 locus. The top hit, rs56113850, 420 
located in intron 4 of CYP2A6, also replicated in the EA participants from the smaller GWAS of 421 
laboratory-based NMR (35). A subsequent GWAS of urinary NMR, conducted in ~2,200 422 
smokers (including n=364 AA) from a prospective multi-ethnic cohort study, identified 248 423 
variants (~99% of which were within or near CYP2A6) significantly associated with the NMR, 424 
and replicated this top hit (rs56113850) (36). The rs56113850 variant was also significantly 425 
associated with the NMR in PNAT2 (P=1.30e-10, beta = 0.46 per C versus T allele, SE= 0.069) 426 
and KIS3 (P=8.02e-12, beta = 0.45 per C versus T allele, SE = 0.064) AA smokers, suggesting, 427 
as for rs12459249, a common ancestral origin. The demonstrated influence of rs12459249 and 428 
rs56113850 on the NMR in a variety of ethnic groups combined with their high variant allele 429 
frequencies (~30-60% in individuals of European and African descent) and only moderate LD 430 
(r2=0.46 and <0.20 in European and African descent individuals, respectively; 1000 Genomes 431 
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data), suggest that these SNPs should be routinely included in genotyping platforms for genomic 432 
investigations of nicotine metabolism and smoking cessation. GTEx expression quantitative trait 433 
loci analyses suggest rs12459249 is associated with CYP2A6 protein expression in the lung, and 434 
possibly liver (effect size=0.12 for C vs. T), while rs56113850 has a greater relative (vs. 435 
rs12459249) influence on liver CYP2A6 mRNA expression (effect size=0.26 for C vs. T). 436 
Because the NMR is 80% heritable (estimated in Finnish twins) (16), largely mediated by 437 
a single enzyme (i.e., CYP2A6), and not appreciably altered by environmental factors (17), the 438 
usefulness of CYP2A6 genetics for personalizing therapy and understanding tobacco-related 439 
disease risk shows great promise. However, the NMR can only be reliably used to assess 440 
CYP2A6 activity in current, regular (i.e., daily) smokers (12-14), while CYP2A6 genetics could 441 
be used to predict activity phenotype in current, former, and non-smokers in epidemiological 442 
investigations of cancer risk, for example. Thus, it is likely that a CYP2A6 genetics-based 443 
approach could have greater utility and wider applicability compared to the NMR. In addition, 444 
because CYP2A6 also metabolizes therapeutic drugs including letrozole (53) and tegafur (54), 445 
two chemotherapeutics, as well as other drugs (e.g., efavirenz, metronidazole, artemisinin, 446 
valproic acid) (55), the usefulness of CYP2A6 genetics in personalized medicine approaches 447 
extends beyond tobacco dependence.  448 
Several limitations of our work warrant mention. By virtue of the genome-wide 449 
genotyping chip, we were unable to adequately examine structural variation in CYP2A6. Copy 450 
number variation, such as the CYP2A6*1XA duplication and CYP2A6*4 deletion variants (46), is 451 
known to alter CYP2A6 activity; it is possible that known and/or novel copy number variants in 452 
CYP2A6 are in LD with the variants identified in our study. In addition, the lack of overlap in 453 
signals observed between AA and European descent smokers may be due, in part, to differences 454 
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in the genotyping platforms used, reference panels for imputation, quality 455 
control/imputation/MAF filtering pipelines, as well as potential inter-ethnic variation in 456 
environmental confounding factors and/or additional potential differences between smokers 457 
seeking treatment versus those that are not. However, head-to-head comparisons of NMR GWAS 458 
signals in PNAT2 AA and PNAT2 European descent smokers, analyzed using an identical 459 
genotyping platform and phase I release of 1000 Genomes, also indicate a substantial lack 460 
overlap (unpublished observations). Finally, analyzing treatment-seeking smokers may limit 461 
generalizability to general smoking populations, however personalized medicine approaches 462 
based on CYP2A6 or the NMR would be targeted to treatment-seeking smokers and future 463 
GWAS in treatment-seeking smokers from other ethnic backgrounds should be considered. 464 
Future larger studies may identify important signals outside of CYP2A6 that influence the NMR. 465 
In summary, we identified three independent signals in the largest NMR GWAS of AA 466 
smokers performed to date, accounting for ~20% of the total variability in the NMR. Over half 467 
(~60%) of the 96 total hits were not found in the largest NMR GWAS of European descent 468 
smokers (16), and might contribute to unique regulation of CYP2A6 in AA. Further investigation 469 
of these hits, including haplotype characterization and functional assessments will help identify 470 
which variants are causally influencing the NMR beyond known functional variants (e.g., 471 
CYP2A6*17 (33)). There may also be rare CYP2A6 variants (56, 57) with substantial impacts on 472 
the NMR; future sequencing-based studies will complement GWAS approaches and may further 473 
improve our understanding of the genetic influences on the NMR. Determining whether these 474 
genetic variants influence other phenotypes including smoking cessation will set the stage for 475 
genomics-based personalization of tobacco dependence treatment. Functional characterization 476 
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studies may also provide insight into inter-ethnic variability in nicotine metabolism/CYP2A6 477 
activity and resulting smoking behaviours and tobacco-related disease risk. 478 
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Table 1. Characteristics of African American smokers from the three clinical trial samples 672 






% Female (N) 50.4 (254) 66.4 (299) 69.6 (334) 
Age, mean (SD); range 47.3 (9.8); 20-65 46.8 (11.6); 19-80 45.0 (11.2); 19-81 
BMI, mean (SD); range 30.5 (7.1); 17.6-58.3 31.2 (7.8); 14.8-68.4 30.5 (8.0); 14.0-73.5 
Cigarettes/day, mean (SD); 
range 
16.3 (6.3); 5-40b 7.8 (2.6); 1-17 7.6 (3.3); 0-30 
Cotinine in ng/ml, mean 
(SD), median; range 
274.2 (130.4), 252.7; 32.2-
837.3 
243.7 (122.4), 233.2; 13.7-
680.7 
248.9 (144.9), 235.9; 10.1-
927.3 
NMR, mean (SD), median; 
range 
0.33 (0.20), 0.28; 0.0090-
1.17 
0.38 (0.26), 0.33; 0.02-1.79 0.33 (0.23), 0.27; 0.02-1.70 
Abbreviations: PNAT, Pharmacogenetics of Nicotine Addiction Treatment; KIS, Kick-It-At-Swope; SD, standard deviation; 673 
BMI, body mass index; NMR, nicotine metabolite ratio 674 
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Table 2. Top 10 overall genetic variants significantly associated with the NMR in the meta-676 
analyzed GWAS results from PNAT2 and KIS3 African American smokers 677 























Beta (SE);  
P-Valueb in 
KIS3 
rs12459249 Imputed in 
PNAT2 (0.99) and 
KIS3 (0.99) 
~9.5kb 3’ of 
CYP2A6 







rs10853742 Imputed in 
PNAT2 (0.99) and 
KIS3 (0.99) 
~8.9kb 3’ of 
CYP2A6 







rs11667314 Imputed in 
PNAT2 (0.98) and 
KIS3 (0.98) 
~8.5kb 3’ of 
CYP2A6 







rs11878604 Imputed in 
PNAT2 (0.97) and 
KIS3 (0.95) 
~16kb 3’ of 
CYP2A6 








rs11083569 Imputed in 
PNAT2 (0.95) and 
KIS3 (0.95) 
~9.1kb 3’ of 
CYP2A6 







rs56267346 Imputed in 
PNAT2 (0.97) and 
KIS3 (0.96) 








rs111825958c Genotyped in 
PNAT2 (N/A); 
imputed in KIS3 
(0.92) 
~17kb 3’ of 
EGLN2 








rs12986371 Genotyped in 
PNAT2 (N/A) and 
KIS3 (N/A) 
~5.7kb 3’ of 
CYP2A6 







rs111645190 c Imputed in 
PNAT2 (1.0)  
and KIS3 (0.99) 
~5.5kb 5’ of 
CYP2A6 










rs145638254c Imputed in 
PNAT2 (1.0)  
and KIS3 (0.99) 
~4.7kb 5’ of 
CYP2A6 








MAF, minor allele frequency; N/A, not applicable 678 
aIn PNAT2, GWAS results were adjusted for principal components 1 and 2, sex, age, BMI, and the use of mentholated cigarettes. 679 
bIn KIS3, GWAS results were adjusted for principal components 1 and 2, sex, age, and BMI. The genomic inflation factor score 680 
(λ) in each population was 1 and therefore not adjusted for in the meta-analysis. 681 
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Table 3. The variants tagging the top two independent signals from the meta-analysis of 687 
conditional analyses in PNAT2 and KIS3 African American smokers 688 








Beta (SE);  
P-Value in 
PNAT2a 
Beta (SE);  
P-Value in 
KIS3a 
Beta (SE);  
P-Value in Meta-
Analysisb 
rs12459249 ~9.5kb 3’ of 
CYP2A6 






rs111645190 ~5.5kb 5’ of 
CYP2A6 






MAF, minor allele frequency 689 
aAdjusted for cohort-specific principal components 1 and 2 690 
bIn PNAT2, GWAS results were adjusted for principal components 1 and 2, sex, age, BMI, and the use of mentholated cigarettes. 691 
In KIS3, GWAS results were adjusted for principal components 1 and 2, sex, age, and BMI. The genomic inflation factor score 692 
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Figure Legends 723 
 724 
 725 
Figure 1. rs12459249 and rs111645190 tagged the top two independent signals significantly 726 
associated with the NMR from the meta-analysis of conditional analyses in PNAT2 and 727 
KIS3 African American smokers. 728 
The top (i.e., smallest P-value) overall variant associated with the NMR was rs12459249. 729 
LocusZoom plots depicting rs12459249 (indicated with a purple diamond) in PNAT2 and KIS3 730 
are shown in (A) and (B), respectively. P-values are adjusted for principal components 1 and 2. 731 
The second independent signal associated with the NMR was tagged by rs111645190. 732 
LocusZoom plots depicting rs111645190 (indicated with a purple diamond) in PNAT2 and KIS3 733 
are shown in (C) and (D), respectively. P-values are adjusted for principal components 1 and 2. 734 
LD patterns are based upon the hg19/1000 Genomes November 2014 release AFR reference 735 
population. 736 
 737 
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Figure 2. Influence of the top two independent signals, tagged by rs12459249 and 739 
rs111645190, identified in the meta-analysis of conditional analyses on the NMR in PNAT2, 740 
KIS3, and KIS2 smokers.  741 
Associations between rs12459249 and the NMR (not transformed) are shown in PNAT2 742 
(P=1.59e-18) (A), KIS3 (P=3.41e-19) (B), and KIS2 (P=1.30e-17) (C) African American 743 
smokers using boxplots. Associations between rs111645190 and the NMR (not transformed) are 744 
shown in PNAT2 (P=4.10e-10) (D), KIS3 (P=6.88e-14) (E), and KIS2 (P=1.77e-7) (F) African 745 
American smokers using boxplots. The box represents the interquartile (IQ) range. The line 746 
across the box indicates the median NMR value. Open circles represent NMR values that are 747 
between 1.5X and 3X the IQ range, while asterisks represent NMR values that are greater than 748 
3X the IQ range. The P-values for PNAT2 and KIS3 are derived from the square-root NMR 749 
GWAS conducted separately in each sample, and are adjusted for cohort-specific principal 750 
components 1 and 2 and NMR covariates. The P-values for KIS2 are derived from additive linear 751 
regression models of square-root NMR adjusting for sex, age, and BMI. In KIS2, n=5 752 
individuals with NMR values of 1.70, 1.52, 1.45, 1.37, and 1.36 are omitted from the graph but 753 
were included in the analysis. In KIS3, n=5 individuals with NMR values of 1.79, 1.78, 1.56, 754 
1.52, and 1.48 are omitted from the graph but were included in the analysis. 755 
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Figure 3. rs2644890 and rs111825958 were the top unique variants significantly associated 758 
with the NMR in PNAT2 and KIS3 African American smokers, respectively. 759 
The top (i.e., smallest P-value) unique variant associated with the NMR in PNAT2 was 760 
rs2644890. LocusZoom plots depicting rs2644890 (indicated with a purple diamond) in PNAT2 761 
and KIS3 are shown in (A) and (B), respectively. P-values are adjusted for principal components 762 
1 and 2. The top (i.e., smallest P-value) unique variant associated with the NMR in KIS3 was 763 
rs111825958. LocusZoom plots depicting rs111825958 (indicated with a purple diamond) in 764 
PNAT2 and KIS3 are shown in (C) and (D), respectively. P-values are adjusted for principal 765 
components 1 and 2. LD patterns are based upon the hg19/1000 Genomes November 2014 766 
release AFR reference population. 767 
 768 
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Figure 4. Influence of the top unique variants, rs2644890 and rs111825958, on the NMR in 770 
PNAT2, KIS3, and KIS2 smokers.  771 
Associations between rs2644890 and the NMR (not transformed) are shown in PNAT2 772 
(P=2.04e-12) (A), KIS3 (P=5.95e-7) (B), and KIS2 (P=5.60e-5) (C) African American smokers 773 
using boxplots. Associations between rs111825958 and the NMR (not transformed) are shown in 774 
PNAT2 (P=4.11e-10) (D), KIS3 (P=5.28e-16) (E), and KIS2 (P=4.25e-11) (F) African American 775 
smokers using boxplots. The box represents the interquartile (IQ) range. The line across the box 776 
indicates the median NMR value. Open circles represent NMR values that are between 1.5X and 777 
3X the IQ range, while asterisks represent NMR values that are greater than 3X the IQ range. 778 
The P-values for PNAT2 and KIS3 are derived from the square-root NMR GWAS conducted 779 
separately in each sample, and are adjusted for cohort-specific principal components 1 and 2 and 780 
NMR covariates. The P-values for KIS2 are derived from additive linear regression models of 781 
square-root NMR adjusting for sex, age, and BMI. In KIS2, n=5 individuals with NMR values of 782 
1.70, 1.52, 1.45, 1.37, and 1.36 are omitted from the graph but were included in the analysis. In 783 
KIS3, n=5 individuals with NMR values of 1.79, 1.78, 1.56, 1.52, and 1.48 are omitted from the 784 
graph but were included in the analysis. 785 
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Supplementary Figures 788 
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Supporting Information Legends 793 
 794 
Figure S1. Quality control pipeline utilized in PNAT2 and KIS3 smokers prior to GWAS 795 
analysis.  796 
The quality control (QC) steps for both samples and markers (i.e., variants) carried out prior to 797 
analysis are depicted in chronological order. The original sample sizes were: n=1,687 PNAT2 798 
smokers (self-reported Caucasian, African or African American, Asian, Native American, 799 
Hawaiian/Polynesian, multi-racial, or other), and n=502 KIS3 smokers (self-reported African 800 
American). Sample QC on PNAT2 and KIS3 was performed separately for steps 1 and 2. The 801 
PNAT2 and KIS3 samples remaining following sample QC step 2 were analyzed together for 802 
relatedness (step 3) and ancestry determination (step 4). Remaining sample QC (step 5; 803 
heterozygosity determination) and all marker QC (steps 6-8) were performed separately for 804 
PNAT2 AA and KIS3 AA. The final numbers of samples and markers remaining after sample 805 
and marker QC are indicated in the grey boxes. The final number of PNAT2 AA and KIS3 AA 806 
samples remaining after sample, marker, and biomarker QC (step 9) are indicated in the black 807 
boxes. There were n=406 PNAT2 AA individuals available for final analyses after excluding 808 
those with missing menthol data (n=98), and n=449 KIS3 AA individuals were available for final 809 
analyses after excluding one participant with missing BMI data. 810 
Abbreviations: QC, quality control; IBS, identity by state; PCA, principal components analysis; 811 
PC, principal component; SD, standard deviation; AA, African American 812 
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Figure S2. Ancestry clustering in PNAT2 and KIS3 smokers using HapMap 3 as a 815 
reference population. Principal Components 1 and 2, generated from Sample QC Step 4 (see 816 
Figure S1), are plotted for the whole PNAT2 clinical sample (turquoise open circles), KIS3 817 
(black open circles), and HapMap reference populations: CEU (Utah residents with Northern and 818 
Western European ancestry; red open circles), ASW (African ancestry in Southwest USA; purple 819 
open circles), YRI (Yoruba in Ibadan, Nigeria; green open circles), and CHB (Han Chinese in 820 
Beijing, China; blue open circles). African American ancestry for PNAT2 and KIS3 was 821 
determined using the following cut-points: Principal Component 1 ≤-0.025, and Principal 822 
Component 2 ≤0.01, indicated with black dotted lines. These conservative thresholds were 823 
selected to ensure homogeneity of the population and were chosen based on visual inspection of 824 
the plot.  825 
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Figure S3. Histograms depicting the distribution of the NMR and square-root NMR in 828 
PNAT2, KIS3, and KIS2 African American smokers. The NMR distribution is shown in 829 
PNAT2 (A), KIS3 (B), and KIS2 (C) African American smokers. The square-root NMR 830 
distribution is shown in PNAT2 (D), KIS3 (E), and KIS2 (F) African American smokers. NMR 831 
was square-root transformed to help correct for positive skew. 832 
Abbreviation: SD, standard deviation 833 
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Figure S4. Quantile-quantile (QQ) plots of the square-root NMR GWAS results in PNAT2 836 
and KIS3 African American smokers. QQ plots of the full results of the square-root NMR 837 
GWAS are shown in PNAT2 (A) and KIS3 (B), and after excluding genome-wide significant 838 
hits in PNAT2 (C) and KIS3 (D). Expected P-values are those expected under the null 839 
hypothesis. The shaded area around the red line indicates the 95% confidence interval under the 840 
null.  841 
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Table S1. 2,688 variants included as a custom iSelect® add-on to the Illumina 843 
HumanOmniExpressExome-8 v1.2 array. 844 
 845 
Table S2. Complete list of chromosome 19 variants significantly (P<5e-8) associated with 846 
the NMR in the meta-analysis of PNAT2 and KIS3 African American smokers. 847 
 848 
Table S3. Complete list of chromosome 19 variants significantly (P<5e-8) associated with 849 
the NMR in PNAT2 African American smokers. 850 
 851 
Table S4. Complete list of chromosome 19 variants significantly (P<5e-8) associated with 852 
the NMR in KIS3 African American smokers. 853 
